7123 First-line bevacizumab + reduced-dose interferon-alpha2a in patients (pts) with metastatic renal cell carcinoma (mRCC): an update on overall survival
| Autor: | Melichar, B., Bracarda, S., Bellmunt, J., Ravaud, A., Negrier, S., Jethwa, S., Escudier, B. |
|---|---|
| Zdroj: | In EJC Supplements 2009 7(2):430-430 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect